Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy

The discovery of immune checkpoint blockade has revolutionized the field of immuno-oncology and established the foundation for developing various new therapies that can surpass conventional cancer treatments. Most recent immunotherapeutic strategies have focused on adaptive immune responses by targeting T cell-activating pathways, genetic engineering of T cells with chimeric antigen receptors, or bispecific antibodies. Despite the unprecedented clinical success, these T cell-based treatments have only benefited a small proportion of patients. Thus, the need for the next generation of cancer immunotherapy is driven by identifying novel therapeutic molecules or new immunoengineered cells. To maximize the therapeutic potency via innate immunogenicity, the convergence of innate immunity-based therapy and biomaterials is required to yield an efficient index in clinical trials. This review highlights how biomaterials can efficiently reprogram and recruit innate immune cells in tumors and ultimately initiate activation of T cell immunity against advanced cancers. Moreover, the design and specific biomaterials that improve innate immune cells' targeting ability to selectively activate immunogenicity with minimal adverse effects are discussed.

Automated summary

The discovery of immune checkpoint blockade has revolutionized cancer treatment, but current immunotherapies are only effective for a small subset of patients. Future advancements in cancer immunotherapy will focus on developing novel therapeutic molecules or immunoengineered cells. Biomaterials can efficiently reprogram and recruit immune cells in tumors to activate T cell immunity against advanced cancers.